S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Investing.com - Stifel has reiterated its Buy rating and $35.00 price target on Oculis Holding AG (NASDAQ:OCS), citing progress across the company’s late-stage pipeline. The target represents nearly 97% upside from the current price of $17.80, while InvestingPro data shows the stock has already gained about 50% over the past year.
The firm highlighted OCS-01, a topical dexamethasone formulation, as the most advanced product in development with data expected in the second quarter of 2026. Stifel also noted that OCS-05/privosegtor is emerging as a novel compound for preventing optic nerve degeneration following positive proof-of-concept results.
Oculis is positioned to initiate two additional registrational programs in the second half of 2025, including OCS-02/licaminlimab for dry eye disease after receiving FDA approval on the pivotal trial design. The company is also awaiting a Type C meeting in the third quarter to discuss a Phase 2/3 trial for OCS-05/privosegtor.
The ophthalmology-focused company ended its most recent quarter with $201.3 million in cash, providing runway into early 2028 to reach multiple clinical readouts across its pipeline products.
Stifel sees multiple value-creating opportunities for Oculis as its pipeline expands across ophthalmology indications, including potential applications in anterior ischemic optic neuropathy (AON), non-arteritic anterior ischemic optic neuropathy (NAION), and relapsing-remitting multiple sclerosis (RRMS). With a market capitalization of $972 million and an overall Financial Health score of "Fair" according to InvestingPro, the company appears positioned to pursue these growth opportunities.
In other recent news, Leerink Partners has adjusted its outlook on Oculis Holding AG, raising the stock price target significantly to $50 from a previous target of $22. The firm has maintained its Outperform rating on the company. This change in target price follows discussions with medical professionals and insights gathered during a recent analyst meeting. Analysts at Leerink Partners have expressed increased optimism about Oculis, particularly due to the company’s developments with privosegtor (OCS-05), an SGK activator. SGKs are proteins that promote antioxidant enzymes and regulate genes responsible for cell survival, which can potentially prevent nerve damage. These developments have contributed to a more positive outlook on the company’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.